Stock Ratings / Health Care / AHCO / options

STLN (38) SBC (75) OMDA (55) INNV (52) ⌘ Pro Terminal →

AdaptHealth Corp. (AHCO) Options Positioning, Max Pain & Unusual Sweeps

Q: Where is AHCO trading relative to its 50-day, 200-day, and 52-week technical levels?

AHCO last traded at $5.81 (-2.02% on volume of 2,225,409 shares), positioning the stock -1.36% below its 50-day simple moving average ($5.89) and -36.64% below its 200-day simple moving average ($9.17). Across its 52-week range of $5.21 to $13.43, AHCO sits at the 7.3% percentile with a 14-day RSI of 48.1 (NEUTRAL RANGE) and an implied next-earnings move of ±8.9% ($5.29 to $6.33).

Q: What is AHCO's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for AHCO.

$5.81 -2.02% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $5.78

AdaptHealth Corp. (AHCO) carries a Roarable Rating of D- (Sell) with 35/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (35/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • RED ALERT Cap $808.5M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on AHCO Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is AHCO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, AdaptHealth Corp. (NASDAQ: AHCO) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 35/100 at a spot price of $5.81 (-2.02% 1D, market cap $808.5M). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, AHCO ranks #674 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does AHCO compare to STLN and SBC in the Health Care sector?

▼

Within the Health Care sector (Medical/Nursing Services), AHCO carries a Roarable D- (35/100 RQD), trailing P/E of N/A, gross margin of 18.8%, and ROIC of 2.2%. By comparison, STLN (Starling Oncology Inc.) holds a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $677.7M) and SBC (SBC Medical Group Holdings Incorporated) posts a B grade (75/100 RQD, P/E 11.5x, ROIC 63.1%, cap $585.2M). Among the 5-stock peer group, SBC leads on earnings multiple (11.5x) while SBC leads on capital efficiency (63.1% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for AHCO?

▼

Per AHCO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001725255), AdaptHealth Corp. generated $3.24B in revenue (-0.5% YoY), -$70.8M in net income, and $219.4M in free cash flow against $4.32B in total assets and $1.72B in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $5.78 (-0.55%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 10/20 (D) • 6.8% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (35/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.5% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-10.3% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for AHCO)Realized 20D OHLCV Swing Band: ±8.9%

Deterministic 5-Pillar Attribution (35/100 Composite)

🔍 WHY AHCO SCORES 35/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Cash Engine Quality+10/20 pts (29% of score)

SEC XBRL FY 2025 (10-K): 6.8% FCF Margin ($219.4M FCF) & 18.8% Gross Margin

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (23% of score)

Altman Z-Score 0.79 (DISTRESS RISK (<1.8)) • Piotroski F-Score 4/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$6.14-4.2% Next Q

Q2 (-2Q)

Grade D$5.88+0.9% Next Q

Q3 (-1Q)

Grade E$5.93-2% Next Q

Current

Grade D-$5.81-8.5% Hist 90D α

Trajectory: D (43) → D- (35)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a AHCO Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While AHCO currently carries a cautious 35/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($5.89) and Max Pain ($6.10) forces dealer call-delta covering toward $14.10.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $AHCO• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “AHCO Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 35%NO 65%Trade / Inspect Odds →

CALL VS. PUT WHALE SHARE

— (No Active Options Snapshot)

Put/Call Ratio: — (No Active Options Snapshot)

MAX-PAIN EXPIRATION MAGNET

— (No Active Options Snapshot)

No active options chain max-pain snapshot on file

HISTORICAL 20D VOLATILITY SWING

±8.9%

Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (AHCO)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for AHCO.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring AHCO)

✓Walkthrough of AHCO's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

AHCO // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -55.44%⚡ TESTING RESISTANCE

2026-11-02O $6.03H $6.03L $5.81C $5.81VOL 2.08M

RES: $6.42SUP: $5.71SMA50: $5.89SMA200: $9.17

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

AHCO Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 AHCO Butterfly Map → + Track AHCO →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

-6.4%/yr Implied 5Y Growth

vs. -0.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on AHCO today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for AHCO. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for AHCO today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (AHCO)

Health Care Rank #674 of 1016 ⚔️ STLN vs AHCO Full Matrix →

1. Head-to-Head Health Care Peer Comparison (AHCO vs. STLN, SBC, OMDA, INNV)

Industry: Medical/Nursing Services (29 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, AdaptHealth Corp. (AHCO) ranks #674 by composite RQD confidence (35/100, grade D-) and #386 by equity capitalization ($808.5M). Within this direct 5-issuer industry benchmark cohort, SBC leads on earnings valuation at 11.5x trailing P/E, while SBC leads on capital efficiency and profitability with 63.1% ROIC and 73.3% gross margin. SBC currently holds the highest overall quantitative score in the immediate peer group at 75/100 (B) compared with AHCO at 35/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
AHCO ACTIVE AdaptHealth Corp.	D-	35/100	—	18.8%	2.2%	-2.02%	$808.5M	Benchmark Subject
STLN Starling Oncology Inc.	D-	38/100	—	—	-35.0%	-1.80%	$677.7M	/stln-vs-ahco →
SBC SBC Medical Group Holdings Incorporated	B	75/100	11.5x	73.3%	63.1%	-7.29%	$585.2M	/sbc-vs-ahco →
OMDA Omada Health Inc.	D+	55/100	—	65.7%	-15.7%	-4.68%	$1.20B	/omda-vs-ahco →
INNV InnovAge Holding Corp.	D+	52/100	—	18.0%	-10.2%	-0.54%	$1.26B	/innv-vs-ahco →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001725255

In its most recent audited fiscal period (FY2025, filed 2025-12-31), AdaptHealth Corp. (AHCO) reported GAAP revenue of $3.24B (-0.5% vs. FY2024 revenue of $3.26B , and +1.4% cumulative change since FY2023) , GAAP net income of -$70.8M, operating cash flow of $601.8M, and free cash flow of $219.4M (-7.0% YoY). On the balance sheet, AHCO closed FY2025 with $4.32B in total assets against $1.72B in total debt (Altman Z-Score: 0.79, Piotroski F-Score: 4/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$3.24B	-$70.8M	$601.8M	$219.4M	$4.32B	$1.72B
FY2024 (FY)	2024-12-31	$3.26B	$90.4M	$541.8M	$235.8M	$4.49B	$1.96B
FY2023 (FY)	2023-12-31	$3.20B	-$678.9M	$480.7M	$480.7M	—	—

3. AHCO Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is AHCO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does AHCO compare to STLN and SBC in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for AHCO?

Where is AHCO trading relative to its 50-day, 200-day, and 52-week technical levels?

AHCO last traded at $5.81 (-2.02% on volume of 2,225,409 shares), positioning the stock -1.36% below its 50-day simple moving average ($5.89) and -36.64% below its 200-day simple moving average ($9.17). Across its 52-week range of $5.21 to $13.43, AHCO sits at the 7.3% percentile with a 14-day RSI of 48.1 (NEUTRAL RANGE) and an implied next-earnings move of ±8.9% ($5.29 to $6.33).

AHCO Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is AHCO's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for AHCO.

Direct Sub-Reports: AHCO RQD Cockpit AHCO 12M Forecast AHCO Earnings & Move AHCO Dividends & DRIP AHCO Insiders & 13F AHCO Whale Options AHCO Profit Sankey AHCO News & Why

ROARABLE RATING BRIEF • RQD 35/100 (D-) ✓ STAGE-C NUMBER FIREWALL VERIFIED

AHCO — AdaptHealth Corp.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:32:45Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, AHCO holds an RQD score of 35 out of 100, a letter grade of D-, and the verdict label "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillars are:

Fundamental Cash Engine (10 / 20): Per the Roarable RQD rating, this pillar reflects ROIC of 2.2% and an FCF yield of 0%. Low returns on invested capital and no free-cash-flow yield at the current price indicate limited cash generation relative to the valuation an investor is paying.
Whale 13F Flow (6 / 20): Per the Roarable RQD rating, institutional accumulation and options positioning score modestly. The source data does not itemize the underlying 13F holdings, so the magnitude of institutional support cannot be sized.
Insider Conviction (5 / 20): Per the Roarable RQD rating, SEC Form 4 and Congressional PTR cluster flow score weakly, which suggests limited insider-level conviction in the stock's near-term prospects.
Macro Regime Fit (6 / 20): Per the Roarable RQD rating, beta of 1.0 and sector sensitivity score modestly, meaning the stock moves roughly in line with the market and carries sector-specific exposure.
Forensic Balance Sheet (8 / 20): Per the Roarable RQD rating, the Altman Z of 0.79, Piotroski F of 4/9, and Debt/Equity of 1.13 point to a stretched balance sheet with elevated distress and leverage risk.

Investor implications: the upside case rests on a turnaround in operating margin and cash conversion, which the RQD pillars do not yet show. The valuation tradeoff is that EV/EBITDA of 6.1 may look inexpensive, but with an FCF yield of 0% and a Z-Score in the distress zone, a low multiple can reflect risk rather than mispricing. Balance-sheet fragility means the equity is sensitive to any further earnings or refinancing pressure.

Business

AdaptHealth Corp. (AHCO) is a NASDAQ-listed issuer in the Health Care sector, operating in Medical/Nursing Services. Per the company profile, it is classified within the Medical/Nursing Services industry. The source data does not itemize its product lines, customer base, or revenue model beyond the reported financial figures.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$3244.9M	$90.9M	$-70.8M	N/A	$219.4M	N/A	$1716.0M
FY 2024	$3261.0M	$263.7M	$90.4M	N/A	$235.8M	N/A	$1964.9M
FY 2023	$3200.2M	$-598.4M	$-678.9M	N/A	$480.7M	N/A	N/A

Per the SEC financials, revenue was broadly flat across the three periods, while operating income fell from $263.7M in FY 2024 to $90.9M in FY 2025 and net income swung from $90.4M to $-70.8M. Per the market data, gross margin is 18.8%, operating margin 2.8%, and net margin -2.2%, with ROIC at 2.2%. Per the Roarable RQD rating, the Altman Z-Score is 0.79 and the Piotroski F-Score is 4/9, both weak readings. Per the SEC financials, reported debt declined from $1964.9M to $1716.0M, but Debt/Equity of 1.13 per the Roarable RQD rating still signals a leveraged balance sheet.

Recent Catalysts & News Wire Analysis

Per the recent news feed, the near-term catalyst is the company's earnings event: one headline references a Q3 2026 earnings preview with a claimed GF Value upside of 61%, a TradingView item notes earnings are due the following day, and a Stock Titan item states results will be discussed live on Nov. 3 at 8:30 a.m. ET. Per the news feed, Simply Wall St carries a stock forecast item and Yahoo Finance carries a forecast item, though their contents are not included in the source data. The one flagged risk-watch item is a kalkine.ca report that AHCO was up 8.32% over a week despite a 1.26% drop on October 14, tagged RISK WATCH. The remaining items are tagged YELLOW (market wire). Per the Butterfly Supply-Chain Graph, no proprietary signals or supply-chain links are present.

Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples

Per the Butterfly Supply-Chain Graph, supply chain is listed as NONE, with no butterfly links and no proprietary signals. Upstream and downstream dependencies, sector correlations, and second-order bottlenecks cannot be mapped from the source data. Investors should note that the sector and industry classifications are the only ripple-relevant context provided.

Open Questions

What are the reported EPS, P/E, and forward P/E figures, given that these fields are absent from the source data?
What is the cash balance in each period, since cash is N/A across all reported years?
What drove the swing from $90.4M net income in FY 2024 to $-70.8M in FY 2025, and how much of it is recurring?
What are the 13F holder identities and magnitudes behind the whale flow score?
What did the Q3 2026 earnings release report, and does it confirm or contradict the turnaround narrative?

AHCO Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for AdaptHealth Corp. (AHCO) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to AHCO Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance • 14h ago

Earnings To Watch: AdaptHealth Corp (AHCO) Q3 2026 -- GF Value Sees 61% Upside

Yahoo Finance report covering AdaptHealth Corp. (AHCO) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 17h ago

AdaptHealth (AHCO) reports earnings tomorrow: what to expect

TradingView report covering AdaptHealth Corp. (AHCO) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 20h ago

Home medical equipment provider AdaptHealth will discuss results live Nov. 3 at 8:30 a.m. ET.

Stock Titan report covering AdaptHealth Corp. (AHCO) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Simply Wall St • 23h ago

AdaptHealth (NasdaqCM:AHCO) Stock Forecast & Analyst Predictions

Simply Wall St report covering AdaptHealth Corp. (AHCO) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH kalkine.ca • 1d ago

Why Is AdaptHealth (NYSE:AHCO) Up 8.32% in a Week Despite a 1.26% Drop on October 14?

kalkine.ca report covering AdaptHealth Corp. (AHCO) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

AdaptHealth Corp. (AHCO) Stock Forecasts

Yahoo Finance report covering AdaptHealth Corp. (AHCO) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Simply Wall St • 1d ago

3 Medicare Home Health Stocks That Could Gain From The $90 Part B Payment

Simply Wall St report covering AdaptHealth Corp. (AHCO) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Yahoo • 12d ago

1 Unprofitable Stock on Our Buy List and 2 We Turn Down

Unprofitable companies can burn through cash quickly, leaving investors exposed if they fail to turn things around. Without a clear path to profitability, these businesses risk running out of capital or relying on diluti

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

AHCO Bull vs. Bear Conversation Board — What's Your Call at $5.81?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON AHCO 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $5.22 (-12.0%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is AHCO (D- • RQD 35/100) a Buy at $5.93?

Welcome to the AHCO (AdaptHealth Corp.) Roar Pit. Current RQD Composite is 35/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Medical/Nursing Services. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

RE RedlineAuditor Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $4.80 (-19.1%)

Spot @ $5.93

Pump the brakes on AHCO — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on AHCO, but look at what you are paying: current EV/EBITDA multiples with 18.8% gross margins. Unless AdaptHealth Corp. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

SI SiliconVal_Bull Verified K Arena Trader 🐂 BULLISH 🎯 Target: $7.23 (+21.9%)

Spot @ $5.93

AHCO cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on AHCO, the market is fixating on short-term headline noise in Medical/Nursing Services and ignoring the balance sheet and cash flow trajectory. At $5.93 (52-wk range $5.21 - $13.43), any beat on forward guidance forces shorts and underweight funds to chase.